Objective: To determine the genes underlying Dravet syndrome in patients who do not have an SCN1A mutation on routine testing.
Patients: WES cohort. Probands with Dravet syndrome were recruited from the epilepsy clinic at Austin Health, from the practices of the investigators, and by referral for epilepsy genetics research from Australia and New Zealand. A diagnosis of Dravet syndrome was based on the following criteria: onset less than 15 months of age with convulsive seizures (hemiclonic or generalized) that were often prolonged and triggered by fever. Other seizure types emerged over time, including focal, myoclonic, absence seizures, and drop attacks. Development was normal in the first year of life with later slowing and intellectual disability.
The 13 patients subject to WES had been previously screened for SCN1A point mutations using denaturing high-performance liquid chromatography (dHPLC) (n 5 4) or bidirectional sequencing (n 5 9). Small exonic deletion/duplications had also been excluded using SCN1A multiplex ligation-dependent probe amplification and all patients were negative for large copy number variants (reference 10 and unpublished data).
WES and analysis. The exome sequencing libraries of 34 individuals, including 10 parent-proband trios, 1 mother-proband pair, and 2 unrelated probands were prepared using the SeqCap EZ Human Exome Library v2.0 (Roche, Nimblegen). Libraries were sequenced on an Illumina HiSeq, using a 50 bp paired-end read protocol as per the manufacturer's recommendations. Reads were aligned to the human genome (hg19) using the Burrows-Wheeler Aligner, 11 removing all potential PCR duplicates. The Genome Analysis Toolkit 12 was used for base quality recalibrations, realignment around known indels, variant calling, and filtering to retrieve only high-quality variants. We considered only rare, disruptive (missense, nonsense, splice, frameshift) variants that were not present in the ESP6500 control dataset (see URLs in the appendix) for further analysis.
Patients: Targeted resequencing (WES) cohort. We performed targeted resequencing of candidate genes in a cohort of 67 Dravet and Dravet-like patients. All 67 of these patients had been screened for SCN1A mutations previously by the various collaborating institutions. In addition, we performed SCN1A mutation screening using molecular inversion probes and high-throughput sequencing. Only SCN1A-negative patients were included in the validation cohort (n 5 67).
Targeted resequencing of candidate genes. We selected 15 candidate genes (STXBP1, GABRA1, SCN1B, ATP6VOC, SLC8A1,  CLSNT1, NKAIN3, NOL11, RIMS2, KIF1B, CDK5RAP3, ABTB2 , STK31, KDM2B, SPATA13) from the WES analysis for mutation screening in a validation cohort of 67 SCN1A-negative Dravet probands. From the 13 cases in whom WES was performed, we identified candidate genes belonging to one of 3 categories, based on the presence of a rare variant in that gene. Three candidate genes (STXBP1, GABRA1, SCN1B) were previously implicated in epileptic encephalopathies or other epilepsies. An additional 5 genes (ATP6VOC, SLC8A1, CLSNT1, NKAIN3, NOL11) were selected as candidates as we identified a rare, de novo variant in a single proband. Finally, we selected 7 genes with variants that segregated in a recessive manner in a single proband (RIMS2, KIF1B, CDK5RAP3, ABTB2, STK31, KDM2B, SPATA13). We used molecular inversion probes to "capture" exonic regions and 5 flanking intronic base pairs of target genes, and performed massively parallel sequencing and variant detection as described previously. 13, 14 GABA A mutagenesis and in vitro transcription. Human GABA A complementary DNA (cDNA) was cloned into the pGEMHE vector containing a T7 promoter for in vitro transcription. The Gly251Ser mutation was generated using QuikChange SiteDirected Mutagenesis Kit (Agilent Technologies, Santa Clara, CA) with primers forward 59-GAAGAGAAAGATTAGCTACTTTG TTATTCAAACATACCTGCC and reverse 59-GGCAGGTATG TTTGAATAACAAAGTAGCTAATCTTTCTCTTC. Gly251Ser mutation is underlined. The GABRA1 (Gly251Ser) pGEMHE plasmid was verified by DNA sequencing. cRNA was made using linearized cDNA template and in vitro transcription performed using the mMessage mMachine kit (Applied Biosystems/Ambion, Austin, TX).
GABA modulation of wild-type and mutant receptors.
Oocytes from adult female Xenopus laevis were prepared as previously described. 6 Fifty nanoliters of cRNA encoding the wild-type (WT) human A1, B2, and G2L and mutant A1 (Gly251Ser) GABA receptor subunits (12 ng/mL; stocks confirmed spectrophotometrically and by gel analysis) were injected into the cytoplasm of stage 5 or 6 oocytes using the Roboocyte Robot (Multi Channel Systems, Reutlingen, Germany) and stored for 2 days prior to experimentation. Two-electrode voltage clamp recordings were made in 96-well plates using the Roboocyte automated platform. Oocytes were impaled using recording heads with 2 glass electrodes containing 1.5 M potassium acetate and 0.5 M KCl and held at a membrane potential of 280 mV. Oocytes were continually perfused with a ND96 solution (96 mM NaCl, 2 mM KCl, 0.1 mM CaCl 2 , and 5 mM HEPES, pH 7.5) using a Gilson 222 XL Liquid Handler and Gilson Minipuls 3 Peristaltic Pump (Gilson Medical Electronics, Middleton, WI). To construct a dose-response curve, oocytes were exposed to a 30-second application of test g-aminobutyric acid (GABA) (Sigma Aldrich, Sydney, Australia) (range 1 mM-1 mM) followed by a 60-second wash in ND96 and then a 15-second application of a maximum dose of GABA (1 mM). Only 1 test concentration and 1 maximum concentration of GABA was applied per oocyte. The effect of the test GABA concentration on an individual oocyte was expressed as a percentage of the maximal GABA response in the same oocyte. These percentages were then averaged from many oocytes (range 8-20 oocyes per test dose). Maximum current at 1 mM GABA was also averaged over many oocytes (100 for WT, 97 for Gly251Ser mutation).
RESULTS
We performed WES in 13 SCN1A-negative Dravet syndrome probands (clinical features in table 1), including 10 parent-proband trios, 1 mother-proband pair, and 2 unrelated probands, to identify novel genetic causes for this devastating disorder. On average, we generated 3.8 Gb of mapped sequence data per individual and 92% of bases had .83 coverage across all samples. On average, ;27,000 raw variants were identified in each individual. We prioritized only disruptive (nonsynonymous, splice, frameshift) variants that were not present in the ESP6500 control dataset (see URLs in the appendix) for further analysis and initially applied a de novo model for gene discovery in these patients.
De novo variants. Under a de novo disease model, we identified 15 rare, disruptive variants in 9 individuals, including 2 individuals (T1895, T1911) who were originally sequenced as singletons and whose mutations were confirmed as occurring de novo using Sanger sequencing in the parents (table 2). Five of these de novo variants occurred in known epilepsy genes. Unexpectedly, 3 variants were detected in SCN1A that were not previously identified by Sanger DNA sequencing in 2 and dHPLC in the third. Furthermore, we detected a single mutation in 2 genes previously implicated in other epilepsy syndromes, GABRA1 and STXBP1 (table 2) . We identified 3 additional probands with GABRA1 mutations ( figure 1A ) and 2 patients with de novo STXBP1 mutations by targeted resequencing in 67 patients with a clinical diagnosis of Dravet syndrome (table 2) . Of the 10 trios who underwent WES, 3 probands had no candidate de novo mutations that passed our filtering criteria, whereas 4 subjects had de novo mutations in one or more genes that are not known epilepsy genes (table 2) . Each gene was only implicated in 1 patient, with unique de novo events in 8 genes. In order to validate these genes in Dravet syndrome, we prioritized 5 candidate genes (ATP6VOC, SLC8A1, CLSTN1, NKAIN3, NOL11) for further study. We excluded FARP2, COL6A3, and CYP26C1 as candidate genes given that they encode proteins with no obvious neuronal function or had multiple putatively truncating mutations in the ESP control dataset. Targeted resequencing in these 5 candidate genes in the validation cohort (n 5 67) revealed no additional rare, de novo pathogenic variants.
Inherited mutations in known epilepsy genes. We identified all disruptive variants in known epilepsy genes figure e-1 ). This mutation has been described in families with other types of epilepsy.
15,16
Autosomal recessive model for Dravet syndrome. Given that 2 recessive cases of Dravet syndrome have been reported, 7, 8 we applied this disease inheritance model in the 7 probands without mutations in known epilepsy genes and identified 15 genes with variants that followed an autosomal recessive pattern (variant allele frequency ,1%) (table e-2). Targeted resequencing was performed in 7 candidate genes (RIMS2, KIF1B, CDK5RAP3, ABTB2, STK31, KDM2B, and SPATA13). We excluded the remaining genes as they have been implicated in unrelated disorders (MLL2, PDE6B, PCNT) or have no known or obvious neuronal function (VWA5B2, OAS3, DCHS2, DNAH3, DNAH11). We found no instances of autosomal recessive inheritance in our validation cohort (n 5 67). 7, 8 Dose response of the GABRA1 mutant p.Gly251Ser to GABA. To assess the effect of the p.Gly251Ser GABA A mutation on neuronal function, we measured GABAmediated currents in X laevis oocytes expressing mutant (p.Gly251Ser) GABA A (e-Methods). Maximum current values recorded at 21 mM GABA dosage showed a 2.6-fold reduction in the amplitude of GABAinduced currents in vitro for the p.Gly251Ser mutant (max I 6 SEM: 2,621 6 142, n 5 97) compared to WT (max I 6 SEM: 7,010 6 325, n 5 100) ( figure 1B) . Furthermore, the GABA dose-response curves showed a 5-fold decrease in Figure 1 GABRA1 mutations in epilepsy and effects on g-aminobutyric acid (GABA) response (A) The amino acid locations of the 8 mutations identified in patients with Dravet syndrome (purple) and other epilepsy syndromes (green). There is no clear genotypephenotype correlation with respect to either nature or localization of the mutation and severity of phenotype. (B) Maximal current response (1 mM GABA) of the wildtype (WT) and p.Gly251Ser mutant. (C) GABA dose-response curves of the WT and p.Gly251Ser mutant in Xenopus laevis oocytes. CAE 5 childhood absence epilepsy; EE 5 epileptic encephalopathy; GGE/FS 5 genetic generalized epilepsies/febrile seizures; JME 5 juvenile myoclonic epilepsy.
sensitivity to GABA of the p.Gly251Ser mutant compared to WT ( figure 1C) . DISCUSSION We applied massively parallel sequencing approaches in 67 SCN1A-negative patients with Dravet syndrome to identify novel de novo genetic causes for this devastating disorder. Overall, we show that GABRA1 and STXBP1 are new causes for Dravet syndrome. Furthermore, we identified 3 patients with undetected SCN1A mutations, despite previous mutation screening. This finding verifies the efficacy of our WES approach in gene discovery and the accuracy of clinical diagnosis. Furthermore, we propose that Dravet syndrome is due to mutations in SCN1A more often than the generally reported estimate of 75%, 1 as some mutations pass undetected using conventional mutation detection techniques.
Overall, we identified 4 novel GABRA1 mutations in patients with Dravet syndrome. The clinical presentation was typical for Dravet syndrome, with the only uncommon feature being atonic drop attacks in 2 of the 4 cases. Three of the 4 variants arose de novo, while the inheritance of the fourth variant, a c.335 G.A, p.Arg112Gln in proband T16706, could not be determined as parents were unavailable. However, this same mutation (p.Arg112Gln) arose de novo in another proband (T23532), suggesting this is a recurrent pathogenic mutation resulting in Dravet syndrome. This finding redefines GABRA1 from a gene associated with mild genetic generalized epilepsies and febrile seizures [17] [18] [19] to a gene also implicated in severe epilepsies such as Dravet syndrome ( figure 1A) . Our results are supported by the recent identification of a de novo mutation in GABRA1 in a patient with epileptic encephalopathy. 20 We propose that the p.Gly251Ser GABRA1 mutation reduces the ability of mutant receptors to contribute to phasic inhibition as demonstrated by the decreased sensitivity to GABA and a significantly reduced amplitude of GABA-induced currents. It is likely that the additional 2 missense GABRA1 mutations (p.Arg112Gln, Lys306Thr) act in a similar fashion. Overall, these studies suggest that seizures in these patients are the result of impaired functioning of GABA inhibition in the brain.
We also describe 3 Dravet syndrome patients with de novo missense mutations in STXBP1. Our 3 patients had a Dravet phenotype with onset in the first year of life; however, 2 had both tonic and atonic seizures. Both seizure types are rare early in Dravet syndrome, although tonic seizures are reported in older patients. 21 Status epilepticus was only seen in 1 case. Heterozygous de novo STXBP1 mutations cause early-onset epileptic encephalopathies and neurodevelopmental disorders. Of the .50 patients with STXBP1 encephalopathy described, the majority present by 3 months of age, with Ohtahara syndrome or other early-onset epileptic encephalopathies. [22] [23] [24] [25] [26] [27] [28] [29] [30] [31] [32] Our patients had onset from 6 to 12 months, which is later than usually seen in STXBP1 encephalopathy. It is typically associated with epileptic spasms, and notably these were not observed in our patients with Dravet syndrome. The wide range of STXBP1 mutations show no genotype-phenotype correlation with respect to mutations and clinical presentation (figure e-2).
STXBP1 plays a role in the release of neurotransmitters into the synapse, via regulation of syntaxin. The 3 de novo missense mutations described here all lead to the replacement of a charged residue with a neutral amino acid. These alterations are likely to destabilize the STXBP1 protein or affect binding to syntaxin, as has been shown previously for the Cys180Tyr missense mutation, 22 though experimental validation needs to be performed.
We identified no de novo mutations in proband T22809; however, this individual was shown to carry a maternally inherited c.363C.T (p.Cys121Trp) in SCN1B. This mutation has been described in genetic epilepsy with febrile seizures plus (GEFS1) in 41 affected individuals from 4 families. The affected individuals displayed heterogeneous epilepsy phenotypes ranging from mild (febrile seizures [FS] ) to moderate (temporal lobe epilepsy) and severe (epilepsy with myoclonic-atonic seizures). 15, 16 GEFS1 families may include individuals with Dravet syndrome who also inherit a dominant familial mutation. 33 The p.Cys121Trp mutation affects a highly conserved residue and putatively disrupts a disulphide bridge in the Comment: Dravet syndrome-"Old gene," novel mechanism Dravet syndrome (DS, Online Mendelian Inheritance in Man#607208), or severe myoclonic epilepsy in infancy, is one of the most severe types of genetic epilepsy. Individuals with DS face a high risk of sudden unexpected death in epilepsy. In $75% of cases, DS is associated with mutations of the gene encoding the a1 subunit of the sodium channel, SCN1A. However, the genetic causes of DS without mutations in SCN1A remain largely unknown.
Carvill et al. 1 performed whole-exome sequencing in 13 SCN1A-negative DS candidates and targeted resequencing in 67 additional patient candidates to discover novel genes underlying DS other than SCN1A. They identify 2 novel genes, GABRA1 and STXBP1, that have an association with DS; GABRA1 and STXBP1 mutations have been reported in other epilepsies but not in DS. Furthermore, the authors examined and characterized one GABRA1 mutation, p.Gly251Ser, using in vitro electrophysiology techniques. Compared to wild-type, the p.Gly251Ser mutation showed substantial reduction of sensitivity to g-aminobutyric acid. These in vitro functional studies supported their genetic findings that GABRA1 mutation causes DS. Overall, this study presents novel genetic mutations of DS, providing insights for developing new diagnostic testing and drug targets and possibly leading to individualized therapeutic strategies for DS patients with different genotypes. 34 The p.Cys121Trp SCN1B mutation potentially contributes to the presentation of Dravet syndrome in proband T22809 and causes the FS in his mother. Interestingly, it was nonpenetrant in his maternal grandmother, which is in keeping with the low penetrance observed in GEFS1 families. 35 Other unaffected SCN1B c.363C.T (p.C121W) carriers (n 5 6) have been reported, 16 and the variant is present in controls, suggesting other genetic or nongenetic factors modify the epilepsy phenotype. These observations recapitulate those seen in other patients with Dravet syndrome, where ;3-5% of cases have inherited a pathogenic SCN1A variant, typically from a more mildly affected parent with GEFS1. 36 Recently, 2 reports of recessive SCN1B mutations causing Dravet syndrome have been published, although one had an atypical phenotype, 37 but no heterozygous dominant mutations have been reported. 7, 8 Our patient did not carry additional mutations in SCN1B, nor did we identify additional SCN1B mutations in our validation cohort (n 5 67) by targeted resequencing of the gene. Collectively, these results suggest that SCN1B may play a susceptibility role in the pathogenesis of Dravet syndrome, though further investigations are required.
We show that the genetic etiology of SCN1A-negative Dravet syndrome can, in part, be attributed to de novo mutations in GABRA1 and STXBP1. Of note, mutation screening of GABRA1 in cohorts of patients with genetic generalized epilepsy and epileptic encephalopathies have rarely identified pathogenic mutations (data not shown and references 14, 17, 18, and 20) . Our finding of 4 GABRA1 mutations in 77 SCN1A-negative patients with Dravet syndrome suggests that GABRA1 mutations may be largely limited, at least in terms of epileptic encephalopathies, to Dravet syndrome, though further studies are needed. Conversely, STXBP1 mutations are seen in other epileptic encephalopathy phenotypes, suggesting considerable phenotypic heterogeneity compared to GABRA1.
GABRA1 and STXBP1 are significant contributors to SCN1A-negative Dravet syndrome that should be tested in patients with Dravet syndrome negative for SCN1A mutations. With identification of further cases with Dravet syndrome due to these genes, specific phenotypic patterns may emerge that distinguish these rarer causes of Dravet syndrome from those due to SCN1A mutations. We would argue that, in SCN1A-negative individuals, targeted resequencing of known epilepsy genes is a more cost-effective and high-throughput approach to diagnostic testing. 
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